Phase 3 trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving moderately emetogenic chemotherapy (MEC)

被引：6
|
作者：
Schnadig, Ian D.
Modiano, Manuel R.
Poma, Allen
Hedley, Mary Lynne
Martell, Robert E.
Schwartzberg, Lee Steven
机构：
[1] Compass Oncol, Portland, OR USA
[2] US Oncol Network, Portland, OR USA
[3] Arizona Clin Res Ctr, Tucson, AZ USA
[4] TESARO Inc, Waltham, MA USA
[5] Tufts Med Ctr, Div Hematol Oncol, Boston, MA USA
[6] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.9633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9633
引用
下载
收藏
页数：1
相关论文
共 50 条
  • [21] Rolapitant for the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients receiving multiple cycles of emetogenic chemotherapy
    Schwartzberg, L.
    Navari, R.
    Arora, S.
    Powers, D.
    Jordan, K.
    Rapoport, B.
    CANCER RESEARCH, 2017, 77
  • [22] Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients With Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (08) : 6 - 7
  • [23] Aprepitant (APR) for the prevention of chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) in breast and non-breast cancers
    Gralla, R.
    Rapoport, B.
    Brown, C.
    Street, J. C.
    Hardwick, J. S.
    Carides, A. D.
    EJC SUPPLEMENTS, 2009, 7 (03): : 23 - 24
  • [24] Phase III Trial of Casopitant, a Novel Neurokinin-1 Receptor Antagonist, for the Prevention of Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
    Herrstedt, Jorn
    Apornwirat, Wichit
    Shaharyar, Ahmed
    Aziz, Zeba
    Roila, Fausto
    Van Belle, Simon
    Russo, Mark W.
    Levin, Jeremey
    Ranganathan, Salabha
    Guckert, Mary
    Grunberg, Steven M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (32) : 5363 - 5369
  • [25] Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy
    Rapoport, Bernardo
    Schwartzberg, Lee
    Chasen, Martin
    Powers, Dan
    Arora, Sujata
    Navari, Rudolph
    Schnadig, Ian
    EUROPEAN JOURNAL OF CANCER, 2016, 57 : 23 - 30
  • [26] ANALYSIS OF PALONOSETRON VS ONDANSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) IN PEDIATRIC PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY (MEC/HEC)
    Kovacs, G.
    Wachtel, A. E.
    Basharova, E. V.
    Spinelli, T.
    Nicolas, P.
    Kabickova, E.
    PEDIATRIC BLOOD & CANCER, 2014, 61 : S108 - S108
  • [27] Incidence of chemotherapy-induced nausea and vomiting (CINV) after highly and moderately emetogenic therapy in the era of NK-1 inhibitors - perception versus reality
    Perez-Altozano, J.
    Majem, M.
    Calvo, N.
    Moreno, E.
    Feliu, A.
    Gich, I.
    Mangues, A.
    Barnadas, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 184 - 184
  • [28] SAFETY AND EFFICACY OF ORAL PALONOSETRON IN PREVENTING CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV) OVER MULTIPLE CYCLES OF MODERATELY EMETOGENIC CHEMOTHERAPY (MEC)
    Voisin, D.
    Grunberg, S.
    ANNALS OF ONCOLOGY, 2012, 23 : 507 - 507
  • [29] Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients
    Aapro, M. S.
    Arora, S.
    Powers, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [30] Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy
    Molassiotis, Alex
    Nguyen, Allison Martin
    Rittenberg, Cynthia N.
    Makalinao, Alex
    Carides, Alexandra
    FUTURE ONCOLOGY, 2013, 9 (10) : 1443 - 1450
12345